High Velocity Nasal Insufflation Versus Continuous Positive Airway Pressure in COVID 19 Pneumonic Patients

High Velocity Nasal Insufflation Versus Continuous Positive Airway Pressure in COVID 19 Pneumonic Patients With Acute Type 1 Respiratory Failure

compare the efficacy of High-Velocity Nasal Insufflation (HVNI) versus Continuous Positive Airway Pressure (CPAP) in managing COVID 19 pneumonic patients with acute type 1 respiratory failure

A prospective randomized controlled trial was conducted on 108 patients with COVID 19 pneumonia with acute hypoxemic respiratory failure at Mansoura University Hospitals to compare the efficacy of High-Velocity Nasal Insufflation (HVNI) versus Continuous Positive Airway Pressure (CPAP) in managing COVID 19 pneumonic patients with acute type 1 respiratory failure, focusing on the need for invasive mechanical ventilation (IMV) and 28-day mortality. Patients were randomized into two equal groups: HVNI group and CPAP group. Baseline characteristics, respiratory parameters, and clinical outcomes were recorded.

Inclusion Criteria:

• Patients aged above 18 years with COVID 19 pneumonia with acute type 1 respiratory failure were included.

Exclusion Criteria:

• patients with hypercapnic respiratory failure.
• patients with a disturbed level of consciousness and/or a high risk of aspiration
• individuals with hypotension
• patients requiring invasive mechanical ventilation.